China Resources Pharmaceutical Group Limited (CHINARES PHARMA) has published its 13th annual Sustainability/ESG Report, detailing financial, environmental and social performance for the year ended 31 December 2025.
Financial highlights
• Revenue rose 4.6% year-on-year to RMB 269.57 billion. • Net profit reached RMB 9.65 billion, with profit attributable to shareholders of RMB 4.05 billion. • Total assets expanded to RMB 285.81 billion, while net assets stood at RMB 117.46 billion.
ESG ratings and governance
• The Group secured an “AA” rating from MSCI-ESG and an “A-” rating from Hang Seng. • ISO certifications widened: 93 subsidiaries now hold ISO 14001 (environment), 92 have ISO 45001 (occupational health & safety) and 79 carry ISO 50001 (energy management). • The Board remains the top decision-making body for ESG, supported by a multi-tier committee and digital management platform covering indicator collection, monitoring and disclosure.
Climate and resource management
• CO₂-e emission intensity fell to 0.0275 tonnes per RMB 10,000 of output value, a reduction of more than 20% versus the 2020 baseline. • The Group reported total Scope 1 and Scope 2 emissions of 0.74 million tonnes CO₂-e. • Over 100 GWh of green electricity was purchased, while renewable energy usage exceeded 50,000 tonnes of standard coal equivalent. • Distributed photovoltaic projects generated more than 19 GWh of clean power. • Total direct energy consumption reached 105,119 tonnes of standard coal equivalent; indirect energy use was 13.79 billion kWh.
Operational sustainability
• 37 factories have achieved various levels of “green factory” certification; 14 of these were newly accredited in 2025. • Fifteen flagship products obtained carbon-footprint certification, and three subsidiaries completed clean-production audits, bringing the total to 40. • Hazardous-waste generation was 8,217 tonnes, while non-hazardous waste totalled 240,252 tonnes, with a recycling rate exceeding 96%.
Product quality and R&D
• The Group holds 281 quality-system certifications across subsidiaries; 100% of sites maintain GMP/GSP compliance. • R&D spending climbed to RMB 3.20 billion; active R&D projects totalled 442, supported by nearly 3,900 R&D personnel. • Market withdrawals for quality or safety reasons stood at zero in 2025; external sampling pass rate was 99.92%.
Workforce and community
• Total employees increased to 84,111, with females representing 50.4%. • ISO 45001 coverage now spans 92 subsidiaries; no work-related fatalities occurred during the year. • ESG-related training reached more than 140,000 employee participations. • Philanthropic contributions amounted to RMB 370.90 million, including rural healthcare projects that have built 75 village clinics and trained over 3,800 primary-care managers.
Outlook
The Group reiterated its commitment to integrating dual-carbon targets into strategy, continuing green manufacturing upgrades, expanding innovative R&D, and strengthening supply-chain resilience to support its “Health for All” mission and long-term sustainable growth.